Higher doses of anthracyclines are associated with increased risk of breast cancer in women who survived childhood cancer, regardless of whether they have mutations that predispose them to cancer. Read More >>
Two research papers presented by Roche and Foundation Medicine at the 2019 European Society of Medical Oncology Annual Meeting demonstrate both the promise of an innovative precision medicine driven clinical trial (CUPISCO) for patients with cancer of unknown primary, as well as the challenges of identifying eligible patients for the trial.
Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now